BioXcel Therapeutics, Inc. (BTAIQ) Operating cash flow 2017–2025
BioXcel Therapeutics, Inc. (BTAIQ) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$57.6MFY2025 · since FY2017: -$2.2M → -$57.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$57.6M | +20.0% |
| FY2024 | -$72.0M | +53.5% |
| FY2023 | -$155.0M | -14.5% |
| FY2022 | -$135.3M | -64.7% |
| FY2021 | -$82.2M | -23.8% |
| FY2020 | -$66.3M | -144.8% |
| FY2019 | -$27.1M | -100.6% |
| FY2018 | -$13.5M | -515.2% |
| FY2017 | -$2.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More BTAIQ financial trends
BTAIQ RevenueBTAIQ Net incomeBTAIQ Net marginBTAIQ Gross profitBTAIQ Gross marginBTAIQ Operating incomeBTAIQ Operating marginBTAIQ Free cash flowBTAIQ Capital expendituresBTAIQ Return on equityBTAIQ Stock buybacksBTAIQ Dividends paidBTAIQ Total assetsBTAIQ Total liabilitiesBTAIQ Shareholders’ equityBTAIQ overview →